$TPTX

Abeona Therapeutics Inc. reported its Q4 2025 earnings, highlighting advancements in its gene therapy pipeline and an increase in research funding. The company posted a narrower-than-expected loss and provided optimistic guidance for the upcoming fiscal year based on strong demand for its treatments. However, concerns linger regarding the commercial viability of its products and the competitive landscape. Analysts remain divided, with some praising the progress while others call attention to potential regulatory hurdles. The market reacted cautiously, reflecting mixed sentiments among investors.